Table 3.
Epidemiological and clinical–pathological features of patients (Group A vs Group B)
| Characteristics | Total pts (n = 55) | Group A (n = 29) | Group B (n = 26) | |||
|---|---|---|---|---|---|---|
| No. | % | No. | % | No. | % | |
| Sex | ||||||
|
Male Female |
39 16 |
70.9 29.1 |
22 7 |
75.9 24.1 |
17 9 |
65.4 34.6 |
| Age at diagnosis, years | ||||||
|
Mean Median Range |
49.2 47 13–68 |
49.6 47.0 34–67 |
48.0 46.5 13–68 |
|||
| Age at screening, years | ||||||
|
Mean Median Range |
55.2 58 20–73 |
56.0 56.5 34–73 |
53.4 56.5 20–73 |
|||
| Histology | ||||||
|
PTC FTC MTC PDTC |
12 11 24 8 |
21.8 20.0 43.6 14.6 |
8 7 9 5 |
27.6 24.1 31.0 17.3 |
4 4 15 3 |
15.4 15.4 57.7 11.5 |
| TKI at ACTH test | ||||||
|
Lenvatinib Vandetanib Cabozantinib |
30 22 3 |
54.5 40.0 5.5 |
19 9 1 |
65.5 31.0 3.5 |
11 13 2 |
42.3 50.0 7.7 |
| Lines of TKI | ||||||
|
1 2 4 |
45 9 1 |
81.8 16.4 1.8 |
24 4 1 |
82.7 13.8 3.5 |
21 5 0 |
80.8 19.2 0 |